期刊： ANTI-CANCER DRUGS, 2023; 34 (10)
The natural phenolic compound ellagic acid exerts anti-cancer effects, including activity against colorectal cancer (CRC). Previously, we reported tha......
期刊： ANTI-CANCER DRUGS, 2023; 34 (10)
Anticancer drug resistance is one of the biggest hurdles in the treatment of breast cancer. Drug repurposing is a viable option fordeveloping novel me......
期刊： ANTI-CANCER DRUGS, 2023; 34 (2)
Anaplastic lymphoma kinase (ALK) fusion was found in 3-7% of all patients with nonsmall cell lung cancer. The efficacy of ALK-tyrosine kinase inhibito......
期刊： ANTI-CANCER DRUGS, 2023; 34 (2)
MiR-181a suppresses the proliferation of mouse granulosa cells, which participate in polycystic ovary syndrome (PCOS), suggesting the potential role o......
期刊： ANTI-CANCER DRUGS, 2023; 34 (3)
Ovarian cancer is a gynecological tumor with a poor prognosis. The chemotherapy failure and recurrence induced by paclitaxel (Ptx) resistance are the ......
期刊： ANTI-CANCER DRUGS, 2023; 34 (3)
Recently approved agents for post-vascular endothelial growth factor/post-vascular endothelial growth factor receptor (VEGF/VEGFR) inhibitors treatmen......
期刊： ANTI-CANCER DRUGS, 2023; 34 (9)
Immune ch eckpoint inhibitors (ICIs) represent a milestone in advanced nonsmall cell lung cancer (NSCLC). Nevertheless, NSCLC with known oncogenic dri......
期刊： ANTI-CANCER DRUGS, 2023; 34 (1)
GATA binding protein 3 (GATA3) is reported to critically involved in the pathogenesis of neuroblastoma (NB). This study investigated the specific role......
期刊： ANTI-CANCER DRUGS, 2023; 34 (1)
Papillary thyroid carcinoma (PTC) is a common malignancy in endocrine system globally. Accumulating articles have found that circular RNAs (circRNAs) ......
期刊： ANTI-CANCER DRUGS, 2023; 34 (1)
Circular RNAs play an important role in regulating cisplatin (CDDP) resistance in gastric cancer (GC). The aim of this study was to examine the role a......
期刊： ANTI-CANCER DRUGS, 2023; 34 (1)
Cancer patients often suffer from cancer symptoms, treatment complications and concomitant diseases and are, therefore, often treated with several dru......
期刊： ANTI-CANCER DRUGS, 2023; 34 (4)
An elderly female patient with a long-standing history of Kaposi's sarcoma of the lower limbs was referred to the Surgical Department after the subseq......
期刊： ANTI-CANCER DRUGS, 2023; 34 (7)
Gilteritinib is currently approved in China for relapsed/refractory FLT3-mutated acute myeloid leukemia, and it is very important to monitor and repor......
期刊： ANTI-CANCER DRUGS, 2023; 34 (1)
EGFR inhibitors used in the treatment of metastatic wild-RAS colorectal cancer in combination with chemotherapy are associated with dermatologic side ......
